Phase 1 start of treatment for Geographic Atrophy patients
Boehringer initiates Phase 1 evaluation of BI 771716 a treatment for preserving vision of people living with geographic atrophy (GA)
Search
It is about saving lives Alexis Jaliquias feline blood bank
Veterinarian Alexis Jaliquias founded one of the first blood banks for cats in South America
The impact of carbon reduction projects
Boehringer Ingelheim voluntarily contributes to carbon reduction projects that benefit sustainable development.
Circular economy: Taking action to reduce plastic waste
The packaging department team at Yamagata, Japan, managed to reduce their waste plastic material for a greener and more sustainable tomorrow
Boehringer Ingelheim collaborates with Circle Pharma
Boehringer Ingelheim collaborates with Circle Pharma to develop a first-in-class cyclin RxL inhibitor that can halt the growth of cancer cells
Spesolimab Phase II data
New data published in NEJM shows spesolimab improved signs & symptoms of GPP flares
SIRPα antagonist
SIRPα antagonist
Living Independence
Boehringer Ingelheim’s corporate culture is based on values that have been applied since the company was founded in 1885.
Real stories, real impact: fighting rabies
The danger of rabies is often overlooked. The need for action, unseen. Learn how we can eliminate rabies through leveraging education and dog vaccinations.
Respimat re-usable wins Pharmapack Eco-Design Award
The Respimat® re-usable inhaler device has won the 2020 Pharmapack Eco-Design Award. An enhanced version of the Respimat® soft mist inhaler, Respimat® re-usable has a lower environmental impact and is easy for patients to use.
Powered By Our People – A Global IT Community
With state-of-the-art digital tranformation and almost 2,000 colleagues working in IT at our locations across the world, we have powered the unprecedented growth of our global IT team – the people behind our pioneering information technology progress
1885-1948: Innovative beginnings
The Boehringer Ingelheim history from its start in 1885 to 1948, with milestones and important products
Social innovation: catalyst for sustainable health solutions
Supporting social innovators drives sustainable health solutions in underserved communities. Learn more about Boehringer Ingelheim Social Engagements.
The Goals to Improve Living with GPP
An article that describes the current goals to improve the lives of those living with generalized pustular psoriasis
Our Venture Fund on the search for groundbreaking trends
The Boehringer Ingelheim Venture Fund acquires minority stakes in biotech start-ups, and even supports the majority before and during their founding.
Celebrating 20 years of Metacam for cattle
Celebrating 20 years of Metacam (Meloxicam) for cattle
The first liquid solution for hypertension in cats
Boehringer Ingelheim launches Semintra® 10 mg/ml Oral Solution in selected European countries for the treatment of feline hypertension.
Five facts everyone should know about heartworms
Heartworms are dangerous parasites that can infest pets through mosquito bites, causing serious illness. Here are five key facts we all should know about heartworms.
Supporting Fundappas
Supporting Fundappas in Uruguay to improve quality of life of dogs and people.
Refolding of Inclusion Bodies
Refolding of Inclusion Bodies
Central Nervous System Diseases
Find out more about our research and development in central nervous system diseases
FDA approves Jardiance treatment chronic kidney disease
U.S. FDA approves Jardiance® for treatment of adults with chronic kidney disease
Boehringer Ingelheim reaches more patients than ever, innovation drives growth
Boehringer Ingelheim reports a strong performance in 2022.
Generalized pustular psoriasis at EADV 2021
Dr. Emmanuelle Clerisme-Beaty (former Associate Head of Medicine - Inflammation, Boehringer Ingelheim) reflects on developments for GPP at the EADV congress, 2021
BI Focuses COVID-19 Clinical Research on Alteplase
BI focuses its COVID-19 therapy research on the development of alteplase as a potential treatment for COVID-19 patients with severe breathing problems